Company profile

Edward A. Pesicka
Incorporated in
Fiscal year end
Former names
O&m Holding Inc, Owens & Minor Inc
IRS number

OMI stock data



6 Nov 19
14 Dec 19
31 Dec 19


Company financial data Financial data

Quarter (USD) Sep 19 Jun 19 Mar 19 Dec 18
Revenue 2.4B 2.48B 2.46B 2.54B
Net income 1.22M -10.48M -14.1M -261.82M
Diluted EPS 0.02 -0.18 -0.23 -4.36
Net profit margin 0.05% -0.42% -0.57% -10.30%
Operating income 25.31M 16.14M 14.69M -265.7M
Net change in cash 5.46M 16.1M -28.13M -21.52M
Cash on hand 96.8M 91.34M 75.24M 103.37M
Cost of revenue 2.04B 2.12B 2.1B 2.18B
Annual (USD) Dec 18 Dec 17 Dec 16 Dec 15
Revenue 9.84B 9.32B 9.72B 9.77B
Net income -437.01M 72.79M 108.79M 103.41M
Diluted EPS -7.28 1.2 1.76 1.65
Net profit margin -4.44% 0.78% 1.12% 1.06%
Operating income -392.17M 89.25M 199.6M 200.36M
Net change in cash -1.16M -80.97M 24.47M 104.25M
Cash on hand 103.37M 104.52M 185.49M 161.02M
Cost of revenue 8.47B 8.15B 8.54B 8.56B

Financial data from company earnings reports

Financial report summary

  • We face competition and accelerating pricing pressure.
  • We have significant concentration in and dependence on certain healthcare provider customers and Group Purchasing Organizations.
  • Our operating income is dependent on certain significant domestic suppliers.
  • Our inability to adequately integrate acquisitions could have a material adverse effect on our operation.
  • Changing conditions in the United States healthcare industry may impact our results of operations.
  • We are subject to stringent regulatory and licensing requirements.
  • We may not be able to generate sufficient cash to service our debt and other obligations.
  • Our Global Products segment is exposed to price fluctuations of key commodities, which may negatively impact our results of operations.
  • Our credit facilities and our existing notes have restrictive covenants that could limit our financial flexibility.
  • An interruption in the ability of the our business to manufacture products may have a material adverse effect on our business.
  • An inability to obtain key components, raw materials or manufactured products from third parties may have a material adverse effect on our Global Products segment.
  • Compliance with the terms and conditions of Byram’s Corporate Integrity Agreement requires significant resources and, if we fail to comply, we could be subject to penalties or excluded from participation in government healthcare programs, which could seriously harm our results of operations, liquidity and financial condition.
  • We may incur product liability losses, litigation liability, product recalls, safety alerts or regulatory action associated with the products that we source, assemble, manufacture and sell which can be costly and disruptive to our business.
  • We must obtain clearance or approval from the appropriate regulatory authorities prior to introducing a new product or a modification to an existing product. The regulatory clearance process may result in substantial costs, delays and limitations on the types and uses of products we can bring to market, any of which could have a material adverse effect on our business.
  • We may be unable to realize anticipated cost savings and efficiency and productivity gains or may incur additional and/or unexpected costs in order to realize them.
  • Our results of operations may suffer upon the bankruptcy, insolvency, or other credit failure of a customer that has a substantial amount owed to us.
  • Our investment in Fusion5 has not yet generated revenue and may continue to incur losses.
  • Our business and operations depend on the proper functioning of critical facilities and distribution networks.
  • General economic conditions may adversely affect demand for our products and services.
  • We operate within the European Union, including in the United Kingdom and therefore may be affected by the United Kingdom's withdrawal from the European Union.
  • Owens & Minor’s continued success is substantially dependent on positive perceptions of Owens & Minor’s reputation.
  • We may experience competition from third-party online commerce sites.
  • Audits by tax authorities could result in additional tax payments for prior periods, and tax legislation could materially adversely affect our financial results and tax liabilities.
  • Recent significant changes to our executive leadership team and any future loss of members of such team, and the resulting management transitions might harm our future operating results.
  • Our goodwill may become impaired, which would require us to record a significant charge to earnings in accordance with generally accepted accounting principles.
  • The market price for our common stock may be highly volatile.
Management Discussion
  • Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
  • Owens & Minor, Inc., along with its subsidiaries, (we, us, or our) is a leading global healthcare solutions company with integrated technologies, products and services aligned to deliver significant and sustained value for healthcare providers and manufacturers across the continuum of care.
  • On April 30, 2018 (the Acquisition Date), we acquired substantially all of Avanos Medical, Inc.'s (Avanos, previously Halyard Health, Inc.) Surgical and Infection Prevention business, the name “Halyard Health” (and all variations of that name and related intellectual property rights) and its information technology (IT) systems in exchange for $758 million, net of cash acquired. The Halyard business is a leading global provider of medical supplies and solutions for the prevention of healthcare associated infections across acute care and non-acute care markets. This business is reported as part of the Global Products segment.
Content analysis ?
H.S. freshman Avg
New words: Advanced, BPCI, Bundled, cloud, CMS, computing, escrow, extinguishment, focused, hierarchy, maintenance, percentage, prospectively, removing, sum, tender, unrealized
Removed: addition, presentation, record, relating